Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from Sept. 14-16, 2026, at the Lotte New York Palace Hotel.
The presentation is expected to provide investors and industry stakeholders with insights into Kairos Pharma's strategic direction and recent developments. The company is leveraging structural biology to address two critical challenges in oncology: drug resistance and immune suppression. By targeting these mechanisms, Kairos aims to improve the efficacy of existing cancer therapies and potentially extend patient survival.
Kairos Pharma's lead candidate, ENV-105, is an antibody designed to target CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. The company's approach involves reversing drug resistance by inhibiting CD105, thereby restoring the effectiveness of standard therapies across multiple cancer types. This novel mechanism could have significant implications for patients who have limited options after developing resistance to current treatments.
The announcement comes at a time when the oncology field is increasingly focused on combination therapies and overcoming resistance, which remains a major hurdle in cancer care. If successful, ENV-105 could address an unmet medical need, potentially improving outcomes for patients with various cancers. The company's participation in the H.C. Wainwright conference underscores its commitment to engaging with the investment community and sharing its progress.
Kairos Pharma, based in Los Angeles, California, is dedicated to advancing its pipeline and bringing innovative therapies to market. The presentation at the conference will be an opportunity for the company to highlight its scientific approach and clinical milestones.
For more information about Kairos Pharma and its latest updates, interested parties can visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding the conference presentation is available at https://ibn.fm/NrBQD.
As Kairos Pharma prepares to present at this prestigious event, the company is positioned to highlight its potential to make a meaningful difference in the lives of cancer patients. The conference will bring together key players in the investment and biopharmaceutical sectors, providing a platform for Kairos to showcase its innovative research and future plans.
